Zacks Research Increases Earnings Estimates for Surmodics

Surmodics, Inc. (NASDAQ:SRDX) – Zacks Research boosted their FY2025 earnings per share estimates for Surmodics in a research report issued on Tuesday, January 28th. Zacks Research analyst D. Dey now forecasts that the company will post earnings per share of $0.17 for the year, up from their prior estimate of $0.16. The consensus estimate for Surmodics’ current full-year earnings is $0.19 per share. Zacks Research also issued estimates for Surmodics’ Q4 2026 earnings at $0.27 EPS, FY2026 earnings at $0.83 EPS and FY2027 earnings at $0.88 EPS.

SRDX has been the subject of several other research reports. StockNews.com began coverage on shares of Surmodics in a report on Sunday, January 26th. They issued a “hold” rating for the company. Needham & Company LLC reiterated a “hold” rating on shares of Surmodics in a research note on Thursday. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $50.00.

Surmodics Stock Down 0.8 %

Shares of NASDAQ:SRDX opened at $35.48 on Thursday. The stock has a market cap of $507.15 million, a price-to-earnings ratio of -43.80 and a beta of 1.21. The business’s 50 day moving average is $38.81 and its 200 day moving average is $39.21. Surmodics has a 12-month low of $25.17 and a 12-month high of $42.44. The company has a quick ratio of 3.22, a current ratio of 3.96 and a debt-to-equity ratio of 0.25.

Surmodics (NASDAQ:SRDX) last released its quarterly earnings results on Thursday, February 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04. Surmodics had a negative return on equity of 3.79% and a negative net margin of 9.15%.

Institutional Trading of Surmodics

Hedge funds have recently bought and sold shares of the company. Rhumbline Advisers raised its stake in shares of Surmodics by 4.4% during the fourth quarter. Rhumbline Advisers now owns 20,250 shares of the company’s stock worth $802,000 after acquiring an additional 861 shares in the last quarter. R Squared Ltd purchased a new position in Surmodics in the 4th quarter worth $55,000. SG Americas Securities LLC lifted its stake in Surmodics by 22.1% in the fourth quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock worth $275,000 after purchasing an additional 1,255 shares during the last quarter. Modus Advisors LLC bought a new stake in Surmodics in the fourth quarter worth $40,000. Finally, JPMorgan Chase & Co. boosted its position in Surmodics by 192.7% during the third quarter. JPMorgan Chase & Co. now owns 42,470 shares of the company’s stock valued at $1,647,000 after buying an additional 27,960 shares during the period. Institutional investors own 96.63% of the company’s stock.

Insider Activity at Surmodics

In other news, CFO Timothy J. Arens sold 7,009 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total transaction of $276,434.96. Following the transaction, the chief financial officer now directly owns 70,350 shares in the company, valued at approximately $2,774,604. This represents a 9.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.90% of the stock is currently owned by insiders.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).